Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by bilosellhion Jun 10, 2003 12:50am
307 Views
Post# 6156910

RE: Cash

RE: Cashif all the share purchase warrants are exercised from the December 2002 PP and from the current PP then that would add another $5,500,000 to ONC's cash they issued 1M shares at $2 in Dec 2002, and each share came with a one half of a share purchase warrant. each whole warrant could be exercised for $3/common share, until jun 2004. my math comes up with $1.5M for that, or only about 80% less than your figure. Also, remember ONC owns a swack of BCY shares which could be sold when appropriate. i haven't forgotten that those 1.5M - 1.9M bcy shares have a market value of $300 to $400K based on current market prices, and if they were liquidated all at once, they would probably fetch quite a bit less than that, i.e., they would be enough to pay BT & MC & DB & WS's & GG's salary for a month, maybe. i suspect the cash is necessary for a couple of reasons. 1. there is no imminent partnership deal on the horizon. 2. their burn rate has been underestimated - especially once they get into US glio & systemic trials. you are dreaming if you think they have excess cash reserves - even if they had $18M, which they don't. if they do attempt to diversify again after this latest tth fiasco, its yet another large yellow warning flag that these guys lack the necessary focus, commitment and business savvy to make onc succesful based on reolysin.
Bullboard Posts